Methotrexate is a chemotherapy medicine that blocks the ability of leukemia cells to grow and divide. In this study it is given by IV infusion as part of the intensive treatment schedule to help eliminate cancer cells.

Cyclophosphamide is a chemotherapy drug that damages the DNA of rapidly growing cells, including leukemia cells. It is administered intravenously in the trial to add extra killing power to the treatment regimen.

Mercaptopurine is an oral chemotherapy pill that interferes with the production of DNA in leukemia cells, slowing their growth. Patients take it by mouth during the maintenance phase of therapy to keep the disease under control.

Vinorelbine (listed as VINCRISTINE) is a chemotherapy agent given by IV that stops cancer cells from dividing by disrupting their internal scaffolding. It is used in the trial as part of the combination chemotherapy to increase the overall effectiveness against leukemia.

Pegaspargase is an enzyme that removes the amino acid asparagine, which many leukemia cells need to survive. Given intravenously, it helps starve the cancer cells and is included in the protocol as a targeted component of the chemotherapy backbone.

Blinatumomab (marketed as BLINCYTO) is a special immunotherapy that connects a patient’s own immune cells to leukemia cells, directing the immune system to attack the cancer. In the trial it is given as a continuous IV infusion for 28 days, replacing part of the standard post‑induction chemotherapy for certain low‑risk patients.

Cytarabine is a chemotherapy drug that mimics a building block of DNA, causing the leukemia cells to make faulty DNA and die. It is given by IV infusion as a key part of the intensive treatment phases.

Dexamethasone is a steroid medication that reduces inflammation and also helps kill leukemia cells. Taken orally, it is used throughout the treatment to support chemotherapy and help control disease activity.

Tioguanine is an oral chemotherapy drug that interferes with the production of DNA in leukemia cells, helping to keep the disease in remission during the maintenance stage of therapy.

Recombinant L‑asparaginase (Enrylaze) is an enzyme that breaks down asparagine, an amino acid that leukemia cells cannot produce themselves. Administered by IV, it deprives the cancer cells of this nutrient, contributing to their destruction.

Doxorubicin is a chemotherapy agent that inserts itself into DNA, preventing cancer cells from replicating. Given intravenously, it is part of the intensive chemotherapy regimen aimed at eradicating leukemia cells.

Acute lymphoblastic leukemia – A fast‑growing cancer that starts in the bone marrow, where immature lymphoid cells (lymphoblasts) multiply uncontrollably. These abnormal cells enter the bloodstream and can spread to the spleen, liver, and central nervous system. As the number of leukemia cells increases, normal blood formation is reduced, leading to fatigue, easy bruising, and infections. The disease often progresses quickly, with symptoms worsening as more healthy blood cells are displaced. In children and adolescents, the condition typically develops over weeks to months.